Bioengineering can produce tools for use in cutting-edge cell therapies, among other applications.Credit: Philippe Lopez/AFP via Getty Europe is losing ground in one of the most innovation-intensive sectors in biomedicine and health care: bioengineering1. Many advances in biomedicine are technologically driven, for example, the use of artificial intelligence to predict protein structures and rapid genome
Izzy Kadrmas, a medical assistant at Partnership Health Center’s Watershed Clinic in Missoula, Montana, prepares to take Tywon Pugh’s blood for testing. Katheryn Houghton/KFF Health News hide caption toggle caption Katheryn Houghton/KFF Health News MISSOULA, Mont. — Tywon Pugh has seizures that make it hard to find and keep a job. “They called me a
Bites from a lone star tick (Amblyomma americanum), which live on white-tailed deer, are the main cause of α-gal allergy in the United States.Credit: BackyardProduction/Getty Thomas Platts-Mills develops a rash if he eats red meat. The immunologist is one of thousands of people who are diagnosed each year with tick-induced α-gal allergy — a life-threatening
In late 2024, artificial intelligence reached PhD-level performance on scientific-reasoning benchmarks, and in 2025 it approached the measurement ceiling for one such test. In response, I developed an AI module and taught it to incoming biomedical PhD students at Vanderbilt University in Nashville, Tennessee, where I direct AI initiatives for the interdisciplinary graduate pathway. As
Susan Collins, a Republican senator from Maine, has expressed opposition to a proposal from the White House that would give political appointees control over research grants.Credit: Aaron Schwartz/Getty US senators from both sides of the political aisle released a draft spending bill on 2 August that, if passed, would temporarily halt a far-reaching and controversial
Bispecific antibodies (orange and yellow, artist’s illustration) grab onto two different proteins rather than the standard one.Credit: Thom Leach/Science Photo Library Cancer-fighting drugs called bispecific antibodies are having a moment. A growing number are making their way into the clinic, and researchers are developing increasingly elaborate molecules with new capabilities. In the past five years,